CDK4 and head and neck squamous cell carcinoma: A possible hypothesis could be the lack of sufficient tumor control with single agent therapy—Ribociclib, another CDK4/6 inhibitor, was demonstrated to only have a cytostatic effect in HPV-negative HNSCC mouse models and, additionally, had minimal effect on HPV-positive subjects [51].